Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension (Q46229073)

From Wikidata

Jump to navigation Jump to search

scientific article published in December 2008

Language	Label	Description	Also known as
English	Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension	scientific article published in December 2008

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

3

object named as

Louis J Ignarro

1 reference

Europe PubMed Central

20 December 2017

Filomena de Nigris

5

object named as

Filomena de Nigris

1 reference

Europe PubMed Central

20 December 2017

Sharon Williams-Ignarro

6

object named as

Sharon Williams-Ignarro

1 reference

Europe PubMed Central

20 December 2017

author name string

Giuseppe Bruzzese

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

Ettore Crimi

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

Sabina Libardi

7

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

Linda Sommese

8

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

Carmela Fiorito

9

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

Francesco P Mancini

10

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

Francesco Cacciatore

11

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

Antonio Liguori

12

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

language of work or name

0 references

publication date

1 December 2008

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

American Heart Journal

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

156

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

6

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

1154.e1-8

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Defining the role of zofenopril in the management of hypertension and ischemic heart disorders

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Carotid artery intima-media thickness as an indicator of generalized atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Effect of Sulfhydryl and non-Sulfhydryl Angiotensin-Converting Enzyme Inhibitors on Endothelial Function in Essential Hypertensive Patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Compensatory enlargement of human atherosclerotic coronary arteries

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

The role of the renin-angiotensin system in the development of cardiovascular disease

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Renin-angiotensin system and atherothrombotic disease: from genes to treatment

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Role of the renin-angiotensin system in neointima formation after injury in rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Carotid Intima-Media Thickness and Antihypertensive Treatment

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Nitric oxide and atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Relations between vasoactive hormones and diastolic function in hypertensive uraemic patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Rethinking primary prevention of atherosclerosis-related diseases

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind t

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

New trends in anti-atherosclerotic agents.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

New Challenges for ACE-Inhibitors in Vascular Diseases

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Plasma angiotensin-converting enzyme activity and carotid wall thickening

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2008.09.006

Identifiers

10.1016/J.AHJ.2008.09.006

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19033012

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46229073&oldid=2100526858"